Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Among authors: villani p. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.
Torti C, Quiros-Roldan E, Regazzi M, Antinori A, Patroni A, Villani P, Tirelli V, Cologni G, Zinzi D, Lo Caputo S, Perini P, Carosi G; KARINA-SISTHER Collaboration Group of the MASTER Cohort. Torti C, et al. Among authors: villani p. Antivir Ther. 2005;10(4):505-13. Antivir Ther. 2005. PMID: 16038476 Clinical Trial.
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: villani p. New Microbiol. 2005 Apr;28(2):119-25. New Microbiol. 2005. PMID: 16035256 Clinical Trial.
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group. Baroncelli S, et al. Among authors: villani p. Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6. Ann Pharmacother. 2010. PMID: 20371753 Clinical Trial.
Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, Barassi A, Maserati R, Sighinolfi L, D'Arminio Monforte A, Melzi D'Eril GV. Regazzi M, et al. Among authors: villani p. Ther Drug Monit. 2011 Jun;33(3):303-8. doi: 10.1097/FTD.0b013e31821c2772. Ther Drug Monit. 2011. PMID: 21544015 Free article.
299 results